Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of […]
The post ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com